By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct an open, multi-center Phase Ib/II study evaluating the combination of trastuzumab rezetecan (SHR-A1811), adebrelimab (SHR-1316), and famitinib in solid tumors.
SHR-A1811: A HER2-Targeted ADC
SHR-A1811 is a HER2-targeted antibody-drug conjugate (ADC) designed to induce cell cycle arrest and apoptosis in tumor cells. It was recently approved in China for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations who have received prior systemic therapy.
Adebrelimab and Famitinib
Adebrelimab, a PD-L1 monoclonal antibody, received approval in China in March 2023 for first-line extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy. Famitinib, a multi-kinase inhibitor, was approved last month for use with camrelizumab in the second-line treatment of recurrent or metastatic cervical cancer.-Fineline Info & Tech